Onkologie. 2024:18(3):190-192 | DOI: 10.36290/xon.2024.035
Asciminib in treating chronic myeloid leukaemia
- IV. interní hematologická klinika, FN a LF Hradec Králové
Four tyrosine kinase inhibitors (TKIs), imatinib, dasatinib, bosutinib, and nilotinib, have been approved for the first-line treatment of chronic myeloid leukaemia in chronic phase (CML-CP). Clinical trials with second-generation TKIs demonstrated significantly deeper and faster therapeutic responses, but there was no impact on prolonging survival, probably due to the availability of effective treatments for resistant patients. In the second or third line of treatment of CML-CP, the choice of TKIs depends on the cause of treatment failure (resistance or intolerance to the drug), patient comorbidities, and individual therapeutic goals. Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein and its mechanism of action is thus different from that of other TKIs. Asciminib is approved for the treatment of adult patients with CML-CP who were previously treated with at least two TKIs. In addition to its good efficacy, it has the advantage of relatively low toxicity.
Keywords: asciminib, chronic myeloid leukaemia, tyrosine kinase inhibitors.
Accepted: June 18, 2024; Published: June 24, 2024 Show citation
References
- Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966-984.
Go to original source... 
Go to PubMed... - Hehlmann R. The New ELN Recommendations for Treating CML. J Clin Med. 2020;16;9:3671. Go to original source... Go to PubMed...
- Network NCC. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Chronic Myeloid Leukemia. Online: NCCN; 2024
- Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs. imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044-1054. Go to original source... Go to PubMed...
- Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J. Clin. Oncol. 2016;34(20):2333-2340. Go to original source... Go to PubMed...
- Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231-237. Go to original source... Go to PubMed...
- Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393-404. Go to original source... Go to PubMed...
- Schoepfer J, Jahnke W, Berellini G, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61:8120-8135. Go to original source... Go to PubMed...
- Shanmuganathan N, Hughes TP. Asciminib for chronic myeloid leukaemia: Next questions. Br J Haematol. 2022;199: 322-331. Go to original source... Go to PubMed...
- Hochhaus A, Kim DW, Cortes J, et al. With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study. ASH 2023, abstrakt 450. Blood. 2023:(Supplement 1):450-450. Go to original source...
- Cortes J, Lang F, Rea D, et al. Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1. ASH 2023, abstrakt 868. Blood; 2023:(Suppl. 1):6388. Go to original source...
- Hochhaus A, Réa D, Boquimpani C, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer- term follow-up of ASCEMBL. Leukemia. 2023;37(3):617-626. Go to original source... Go to PubMed...
- Hochhaus A, Cortes J, Takahashi N, et al. ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase. ASH 2023, abstrakt 868. Blood. 2023:(Supplement 1):6388. Go to original source...
- Yeung DT, Shanmuganathan N, John Reynolds J, et al. Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study. ASH 2023, abstrakt 865. Blood. 2023:(Supplement1):865. Go to original source...